Hansen's Disease (Leprosy): Current and Future Pharmacotherapy and Treatment of Disease‐Related Immunologic Reactions

@article{Legendre2012HansensD,
  title={Hansen's Disease (Leprosy): Current and Future Pharmacotherapy and Treatment of Disease‐Related Immunologic Reactions},
  author={Davey P Legendre and Christina A. Muzny and Edwin Swiatlo},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2012},
  volume={32}
}
Hansen's disease, also known as leprosy, remains an important public health problem throughout the world, including North America. The causative microbe in Hansen's disease is Mycobacterium leprae, an acid‐fast organism that is difficult to grow in vitro. The nine‐banded armadillo is the major animal reservoir in the United States. Manifestations of disease vary based on host immune response and can range from tuberculoid to lepromatous leprosy (paucibacillary to multibacillary disease). Hansen… 
MULTI-DRUG REGIMENS FOR TREATMENT OF LEPROSY
TLDR
Among three drugs, rifampicin is the most important anti-leprosy drug and is included in regimens for both paucibacillary (PB) and multibACillary (MB) patients.
Complex Type 2 Reactions in Three Patients with Hansen's Disease from a Southern United States Clinic.
TLDR
Three patients with lepromatous leprosy seen at a U.S. HD clinic with complicated type 2 reactions are reported and the differences in presentations and clinical courses highlight the complexity of the disease and the need for increased awareness of unique manifestations of lepromatism in non-endemic areas.
Clinical Characteristics and Treatment of Leprosy
TLDR
Early disease detection, multidrug therapy, frequent clinical follow-up, and proper management of tissue damage and physical disabilities as a result of peripheral nerve damage are key factors to ensure a good outcome for patients.
Recognizing and managing the immunologic reactions in leprosy.
Case of arthritis secondary to leprosy
TLDR
Having good knowledge of musculoskeletal manifestation of leprosy, will help narrow differential diagnosis and will prevent unnecessary diagnostic workup.
A Case of Fluoroquinolone-Resistant Leprosy Discovered after 9 Years of Misdiagnosis
TLDR
A case of misdiagnosed leprosy in a 21-year-old Malagasy male, who, improperly treated, developed secondary mycobacterial resistance to fluoroquinolone, which significantly improved after 6 months of standard regimen with rifampicin, clofazimine, and dapsone.
Pathogenesis and Host Immune Response in Leprosy.
TLDR
Cellular morphology and the genomic uniqueness of M. leprae are presented, and how the pathogen shows tropism for Schwann cells, macrophages and dendritic cells is shown.
Type 1 reaction in leprosy: a model for a better understanding of tissue immunity under an immunopathological condition
TLDR
This review aims to provide a framework from which to approach the great challenges that still persist in T1R management and debate key issues in order to reduce the distance between basic research and the clinic.
Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?
TLDR
This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
TLDR
To replace the standard WHO-MDT, the new combination must be the shortest, simplest and, consequently, most affordable treatment possible.
...
...

References

SHOWING 1-10 OF 79 REFERENCES
Leprosy (Hansen’s disease)
  • R. Bartt
  • Medicine, Biology
    Current treatment options in neurology
  • 2004
TLDR
Opinion statementLeprosy (Hansen’s disease) causes the most common treatable form of neuropathy in the world and most of the cases seen in the US are amongst immigrants.
Resolution of type 1 reaction in multibacillary Hansen's disease as a result of treatment with cyclosporine.
  • R. Frankel, R. Mita, R. Kim, F. Dann
  • Medicine
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association
  • 1992
TLDR
Cyclosporine therapy resulted in prompt and sustained resolution of the type 1 reaction complicating borderline lepromatous Hansen's disease and the implications regarding the immunopathogenesis of type 1 Reaction are discussed.
The clinical and immunological features of leprosy.
TLDR
It is important that the manifestations of the condition are recognized as early as possible so that early nerve damage can be identified and treated rapidly.
The histological diagnosis of leprosy type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis
TLDR
T1R is identified as being under-diagnosed in comparison with clinical assessments, and the need for such studies in other inflammatory conditions is highlighted.
Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission.
  • R. Miller, J. Shen, T. Rea, J. Harnisch
  • Medicine, Biology
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association
  • 1987
TLDR
The effectiveness of CsA in the treatment of ENL is consistent with the hypothesis that aberrant activation of a subset of T-helper cells is involved in the pathogenesis of this reaction.
Type I reaction of Hansen's disease with exposure to adalimumab: a case report.
TLDR
Three biologic anti-TNF agents are approved for clinical use in rheumatoid arthritis, psoriatic arthritis, and seronegative arthropathies: 2 monoclonal antibodies, infliximab and adalimumab, and the fusion protein etanercept.
Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor.
TLDR
The data suggest that anti-NGF antibodies are present in the sera of leprosy patients and may influence the outcome of neuritis, and that CyA might be a useful drug in controlling nerve impairment and pain in leproSy patients.
Rifampin in the treatment of leprosy.
  • W. Bullock
  • Medicine, Biology
    Reviews of infectious diseases
  • 1983
TLDR
The World Health Organization recommends a multidrug regimen that includes intermittent administration of rifampin for the treatment of leprosy, with a low incidence of adverse reactions to the drug.
On the origin of leprosy
TLDR
Using comparative genomics, it is demonstrated that all extant cases of leprosy are attributable to a single clone whose dissemination worldwide can be retraced from analysis of very rare single-nucleotide polymorphisms.
Use of Genetic Profiling in Leprosy to Discriminate Clinical Forms of the Disease
TLDR
Genes belonging to the leukocyte immunoglobulin-like receptor (LIR) family were significantly up-regulated in lesions of lepromatous patients suffering from the disseminated form of the infection.
...
...